Jin Medical International announced plans to acquire Huaxia Qiying Technology Co. for $159.4 million, to be paid in shares, significantly expanding its elderly-care business into integrated senior health. This strategic acquisition, utilizing a VIE structure, is a major growth initiative that has already driven a substantial after-hours stock surge.
Jin Medical International (ZJYL) is acquiring Huaxia Qiying Technology Co. for $159.4 million, paid through the issuance of 71.28 million new Class A ordinary shares. This move is a significant strategic shift, aiming to expand ZJYL's core elderly-care business into a broader integrated senior-health platform, leveraging Huaxia Qiying's ginseng-related biological assets and technology. The market reacted positively, with ZJYL shares surging over 17% after-hours, indicating investor optimism about the growth potential. For traders, this presents a short-term opportunity driven by the positive news, but long-term success hinges on the effective integration of the acquired assets and realization of the expanded business strategy. The use of a VIE structure to navigate foreign ownership restrictions is a common, albeit sometimes scrutinized, approach in China-related deals.